PT  - JOURNAL ARTICLE
AU  - Irsara, Christian
AU  - Egger, Alexander E.
AU  - Prokop, Wolfgang
AU  - Nairz, Manfred
AU  - Loacker, Lorin
AU  - Sahanic, Sabina
AU  - Pizzini, Alex
AU  - Sonnweber, Thomas
AU  - Holzer, Barbara
AU  - Mayer, Wolfgang
AU  - Schennach, Harald
AU  - Loeffler-Ragg, Judith
AU  - Bellmann-Weiler, Rosa
AU  - Hartmann, Boris
AU  - Tancevski, Ivan
AU  - Weiss, Günter
AU  - Binder, Christoph J.
AU  - Anliker, Markus
AU  - Griesmacher, Andrea
AU  - Hoermann, Gregor
TI  - Clinical validation of the quantitative Siemens SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
AID  - 10.1101/2021.02.17.21251907
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.17.21251907
4099  - http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251907.short
4100  - http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251907.full
AB  - Objectives Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections cause Coronavirus Disease 2019 (COVID-19) and induce a specific antibody response. Serological assays detecting IgG against the receptor binding domain (RBD) of the spike (S) protein are useful to monitor the immune response after infection or vaccination. The objective of our study was to evaluate the clinical performance of the Siemens SARS-CoV-2 IgG (sCOVG) assay.Methods Sensitivity and specificity of the Siemens sCOVG test were evaluated on 178 patients with SARS-CoV-2-infection and 160 pre-pandemic samples in comparison with its predecessor test COV2G. Furthermore, correlation with virus neutralization titers was investigated on 134 samples of convalescent COVID-19 patients.Results Specificity of the sCOVG test was 99.4% and sensitivity was 90.5% (COV2G assay 78.7%; p<0.0001). S1-RBD antibody levels showed a good correlation with virus neutralization titers (r=0.843; p<0.0001) and an overall qualitative agreement of 98.5%. Finally, median S1-RBD IgG levels increase with age and were significantly higher in hospitalized COVID-19 patients (median levels general ward: 25.7 U/ml; intensive care: 59.5 U/ml) than in outpatients (3.8 U/ml; p<0.0001).Conclusions Performance characteristics of the sCOVG assay have been improved compared to the predecessor test COV2G. Quantitative SARS-CoV-2 S1-RBD IgG levels could be used as a surrogate for virus neutralization capacity. Further harmonization of antibody quantification might assist to monitor the humoral immune response after COVID-19 disease or vaccination.Competing Interest StatementCJB is board member of Technoclone GmbH. The other authors declare no compet-ing interest.Funding StatementThe study was performed by institutional research funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was performed at the University Hospital of Innsbruck as part of the clinical evaluation of different SARS-CoV-2 serologic assays. All procedures performed in the present study involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Helsinki declaration and its later amendments and were approved by the ethics committee of the Medical University of Innsbruck (ethics commission numbers: 1103/2020, 1167/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authorsCIconfidence intervalCOIcut-off indexCOVID-19Coronavirus disease 2019CVcoefficient of variationICUintensive care unitIgimmunoglobulinNnucleocapsid protein of the SARS-CoV-2 virusRBDreceptor binding domainRT-PCRreverse transcription polymerase chain reactionSspike protein of the SARS-CoV-2 virusSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2TCID50Tissue Culture Infection Dose 50 (median tissue culture infectious dose)WHOWorld Health Organization